Moderna has reported preliminary clinical ... if governments decide they are needed. "We believe that a bivalent booster vaccine, if authorised, would create a new tool as we continue to respond ...

MRNA-1273.213 is under clinical development by Moderna and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Elasomeran + imelasomeran is under clinical development by Moderna and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Booster shot side effects generally only ... who received a Johnson & Johnson vaccine should receive either a bivalent ...

The UK's Joint Committee on Vaccinations and Immunisations (JCVI) has said that Moderna's bivalent COVID-19 vaccine should be used for the autumn booster campaign in adults.

adding that the bivalent Moderna Spikevax booster is safe and effective with the same mild adverse reactions that resolved quickly, Xinhua news agency reported. Clinical trial results showed that ...

British health authorities Monday greenlighted the use of a Moderna COVID-19 ... in what has been dubbed a “bivalent” approach and will be used primarily as a booster for people aged 50 ...

Ministers say the vaccine will now form part of the autumn booster campaign. Moderna thinks 13 million ... It is known as a bivalent vaccine as it takes aim at two forms of Covid.

and Moderna Inc. have been developing their versions of the bivalent vaccine ... Japan is currently providing booster shots for certain segments of the population, including second boosters ...

US pharma giant Pfizer's new bivalent mRNA-based Covid booster vaccine has shown to be highly effective in reducing hospitalisation and deaths, particularly in vulnerable patients aged 65 years ...